Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF – Get Free Report) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 78,634 shares, a decrease of 51.7% from the April 15th total of 162,794 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.
Newron Pharmaceuticals Price Performance
Newron Pharmaceuticals stock remained flat at $20.00 during mid-day trading on Friday. Newron Pharmaceuticals has a 12 month low of $9.10 and a 12 month high of $20.00. The business’s 50 day moving average price is $16.17 and its two-hundred day moving average price is $11.74.
Newron Pharmaceuticals Company Profile
Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.
Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.
Featured Articles
- Five stocks we like better than Newron Pharmaceuticals
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
